Fig. 2
From: The economic burden of bronchiectasis – known and unknown: a systematic review
Distribution of costs in patients with bronchiectasis according to disease severity. Analysis of data from six hospitals (n = 456). Severity was assessed according to the FACED score: mild, 0–2 (i.e. low mortality risk); moderate, 3–4; and severe, 5–7 (i.e. high mortality risk)
Inhalers included long-acting beta-agonists, inhaled corticoids and short- or long-acting anticholinergics. Adapted from de la Rosa et al., 2016 [19]